<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-145466</identifier>
<setSpec>0214-9168</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">High-density lipoprotein as a marker of residual risk in patients treated with statins: prevalence and clinical importance</dc:title>
<dc:description xml:lang="en">Statin treatment reduces the relative risk of a coronary event by approximately 30% and consequently a high residual risk persists. Data from epidemiological, angiographic and intervention studies suggest that this residual risk could be reduced by increasing highdensity lipoprotein cholesterol (HDL-c). Approximately one out of every four patients with chronic ischemic heart disease has low HDL-c concentrations, independently of the use of statins. In this population low HDL-c levels are most frequent in women, patients with diabetes and those with criteria of metabolic syndrome. Therefore, a high percentage of patients with chronic ischemic heart disease could benefit from interventions aimed at increasing HDL-c levels (AU)</dc:description>
<dc:creator>Lahoz Rallo, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tratamiento con estatinas reduce el riesgo relativo de presentar un episodio coronario en alrededor de un 30%, persistiendo, por lo tanto, un elevado riesgo residual. Hay datos procedentes de estudios epidemiológicos, angiográficos y de intervención que sugieren que el incremento del colesterol unido a lipoproteínas de alta densidad (cHDL) podría reducir el riesgo residual. Aproximadamente, 1 de cada 4 pacientes con cardiopatía isquémica crónica presenta valores de cHDL bajos, independientemente del empleo de estatinas, siendo más frecuentes en mujeres, diabéticos y pacientes con criterios de síndrome metabólico. Por lo tanto, un alto porcentaje de pacientes con cardiopatía isquémica crónica se podría beneficiar de intervenciones dirigidas a elevar el cHDL (AU)</dc:description>
<dc:source>Clín. investig. arterioscler. (Ed. impr.);22(supl.1): 9-11, abr. 2010.</dc:source>
<dc:identifier>ibc-145466</dc:identifier>
<dc:title xml:lang="es">Lipoproteína de alta densidad como marcador de riesgo residual en pacientes tratados con estatinas: prevalencia y trascendencia clínica</dc:title>
<dc:subject>^d3343^s22012</dc:subject>
<dc:subject>^d3343^s22044</dc:subject>
<dc:subject>^d8249</dc:subject>
<dc:subject>^d3343^s22053</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d3343^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30650^s22044</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d30650^s22062</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d23568^s22044</dc:subject>
<dc:subject>^d8249^s22002</dc:subject>
<dc:subject>^d36032^s22012</dc:subject>
<dc:subject>^d3942^s22044</dc:subject>
<dc:subject>^d36032^s22016</dc:subject>
<dc:subject>^d3942^s22016</dc:subject>
<dc:subject>^d8249^s22044</dc:subject>
<dc:subject>^d8249^s22011</dc:subject>
<dc:type>article</dc:type>
<dc:date>201004</dc:date>
</metadata>
</record>
</ibecs-document>
